The reason is simple: drug companies are prohibited from pro-actively sharing information about their products for uses beyond what the FDA has approved.
But some of this political thinking is inertia, because for decades, on issues like the roll-out of generic drugs, the regulatory climate, and strong protections for intellectual property, drug companies were clearly better off with the pro-business Republican party.